For research use only. Not for therapeutic Use.
Monomethyl auristatin E intermediate-2 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs)[1].
| Catalog Number | I040258 |
| Synonyms | (2R,3R)-3-(methoxymethoxy)-2-methyl-3-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]propanoic acid |
| Molecular Formula | C15H27NO6 |
| Purity | ≥95% |
| InChI | InChI=1S/C15H27NO6/c1-10(13(17)18)12(21-9-20-5)11-7-6-8-16(11)14(19)22-15(2,3)4/h10-12H,6-9H2,1-5H3,(H,17,18)/t10-,11+,12-/m1/s1 |
| InChIKey | XXJRADINQBEQRW-GRYCIOLGSA-N |
| SMILES | CC(C(C1CCCN1C(=O)OC(C)(C)C)OCOC)C(=O)O |
| Reference | [1]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87. |
